FDA.reportPublic FDA data

cosibelimab-ipdl 300 MG per 5 ML Injection

RxCUI
2717518
RxNorm name
cosibelimab-ipdl 300 MG per 5 ML Injection
Display name
cosibelimab-ipdl 300 MG per 5 ML Injection
Full name
cosibelimab-ipdl 300 MG per 5 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:46

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761297Unloxcytcosibelimab-ipdl351(a)Rx2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
06bdadd5-d2db-406f-a3f8-de47f48a52e3cosibelimab-ipdl 300 MG in 5 ML Injection [PSN] · 5 ML cosibelimab-ipdl 60 MG/ML Injection [SCD] · cosibelimab-ipdl 300 MG per 5 ML Injection [SY] · cosibelimab-ipdl 60 MG/ML per 5 ML Injection [SY]43These highlights do not include all the information needed to use UNLOXCYT safely and effectively. See full prescribing information for UNLOXCYT. UNLOXCYT (cosibelimab-ipdl) injection, for intravenous use Initial U.S. Approval: 202420251208